Jade Biosciences (JBIO) Accounts Payables (2020 - 2026)

Jade Biosciences (JBIO) has 7 years of Accounts Payables data on file, last reported at $4.0 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables rose 5666.67% year-over-year to $4.0 million; the trailing twelve-month figure through Mar 2026 stood at $4.0 million (up 5666.67% YoY), and the FY2025 full-year result was $2.2 million, up 66.74% from the prior year.
• Accounts Payables for Q1 2026 stood at $4.0 million, up from $2.2 million in the prior quarter.
• Across five years, Accounts Payables topped out at $7.6 million in Q2 2025 and bottomed at $69000.0 in Q1 2025.
• The 5-year median for Accounts Payables is $2.9 million (2022), against an average of $3.1 million.
• The widest annual swing landed in 2025, when Accounts Payables plunged 97.92%; it then surged 5666.67% in 2026.
• A 5-year view of Accounts Payables shows it stood at $2.6 million in 2022, then declined by 6.95% to $2.4 million in 2023, then tumbled by 46.16% to $1.3 million in 2024, then surged by 66.74% to $2.2 million in 2025, then jumped by 84.98% to $4.0 million in 2026.
• The last three Accounts Payables figures came in at $4.0 million (Q1 2026), $2.2 million (Q4 2025), and $1.3 million (Q3 2025), per Business Quant data.

Peer Comparison